Mental Health Innovation: Choosing the Right Capital, not just any Capital

This question matters deeply for building positive funding relationships in mental health innovation, both for those providing the capital and for startups, as we explored across our two expert panels. Funding is never neutral. The type of capital a company takes can shape what gets built, how quickly evidence is gathered, who the product is designed for, which markets are prioritised, and whether the long-term needs of patients, clinicians and systems remain in view.

Insights from the founder of the Hemingway Report Steve Duke, and health tech investor Branislav Trajkovski set the stage for a thoughtful discussion of a funding landscape which has seen significant changes in the past five years. As early-stage capital becomes more scarce it is not simply providing access to mental health care that investors are concerned about, but providing provable positive outcomes for patients and clinicians.

In our first panel we explored the different funding options developing companies in the mental health space may have, with discussion focusing around one common theme: that funding is a tool not a goal. Contributions from Exceptional Ventures, Gresham House Ventures, Conduit Connect, and Simplyhealth offered a grounded perspective on the space and challenges for venture capital in mental health funding.

There is, of course, a place for venture capital. Many brilliant companies would not exist without it. However, mental health innovation often sits in a more nuanced landscape: regulated pathways, NHS procurement cycles, clinical evidence requirements, ethical responsibilities, and returns and outcomes that cannot always be captured neatly in short commercial timeframes. Hearing from The Wellcome Trust about alternative funding sources made it clear, intentionality is key when seeking funding.

The perspective of Mindler and myHappymind, two companies with very different funding journeys, brought a nuanced discussion of the pitfalls and benefits of both bootstrapped and venture capital funding for mental health startups.

These nuances for both investors and companies showed that it is not simply a question of finding enough funding for mental health ventures, but how do we help the right capital meet the right innovation, at the right time, with the right expectations?